Eficacia y seguridad del Rivaroxabán versus Warfarina en la prevención de ictus isquémico en la fibrilación auricular

Abstract

Atrial fibrillation (AF) is a cardiac arrhythmia that represents a worldwide public health problem due to its high morbidity, mortality, and disability. Its prevalence and incidence have increased significantly in recent years due to the aging of the population and the increase in chronic diseases. Atrial fibrillation increases the risk of ischemic stroke by up to 5 times. Its treatment is a challenge due to all the perspectives from which it is approached, and one of the main objectives is to reduce the risk of stroke by adequate anticoagulation. In past years, clinical practice guidelines positioned vitamin K antagonists (warfarin) as the first-line drugs. However, they have been widely surpassed by direct-acting oral anticoagulants (rivaroxaban) since they have produced fewer strokes and intracranial hemorrhages in several clinical trials and population-based studies. Conclusion: Finally, rivaroxaban and warfarin are at least as effective and safe in preventing ischemic stroke and bleeding in patients with valvular AF as there were no significant differences between the two.